Axitinib as a third or further line of treatment in renal cancer: a single institution experience.

ABSTRACT:

Background

Kidney cancer is a lethal neoplasm that affects several thousands of people every year. Renal cell carcinoma (RCC) is the most common histologic type. Recent developments in the therapeutic approach include antiangiogenic targeted approaches and Immunotherapy. Thus, the therapeutic algorithm of RCC patients and the survival outcomes have changed dramatically.

Methods

Herein we present a retrospective study of the patients treated in our Department with an antiangiogenic agent -Axitinib, a tyrosine kinase inhibitor- as a third or further line treatment. Statistical analysis was performed with SPSS, including the available clinicopathological data of the patients included.

Results

Axitinib was found to be active in patients who received this treatment beyond

SUBMITTER: Tsironis G 

PROVIDER: S-EPMC7265645 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature